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Abstract: The objective of this study was to assess in vitro the antimicrobial activity of 
ethanolic extract of Polish propolis (EEPP) against methicillin-sensitive Staphylococcus 
aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. 
The combined effect of EEPP and 10 selected antistaphylococcal drugs on S. aureus 
clinical cultures was also investigated. EEPP composition was analyzed by a High 
Performance Liquid Chromatography (HPLC) method. The flavonoid compounds 
identified in Polish Propolis included flavones, flavonones, flavonolols, flavonols and 
phenolic acids. EEPP displayed varying effectiveness against twelve S. aureus strains, with 
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minimal inhibitory concentration (MIC) within the range from 0.39 to 0.78 mg/mL, 
determined by broth microdilution method. The average MIC was 0.54 ± 0.22 mg/mL, 
while calculated MIC50 and MIC90 were 0.39 mg/mL and 0.78 mg/mL, respectively. The 
minimum bactericidal concentration (MBC) of the EEPP ranged from 0.78 to 3.13 mg/mL. 
The in vitro combined effect of EEPP and 10 antibacterial drugs was investigated using 
disk diffusion method-based assay. Addition of EEPP to cefoxitin (FOX), clindamycin 
(DA), tetracycline (TE), tobramycin (TOB), linezolid (LIN), trimethoprim+sulfamethoxazole 
(SXT), penicillin (P), erythromycin (E) regimen, yielded stronger, cumulative antimicrobial 
effect, against all tested S. aureus strains than EEPP and chemotherapeutics alone. In the 
case of ciprofloxacin (CIP) and chloramphenicol (C) no synergism with EEPP was observed. 
Keywords: methicillin-resistant S. aureus (MRSA); methicillin-sensitive S. aureus (MSSA); 
ethanolic extract of Polish propolis (EEPP) 
 
1. Introduction 
The coagulase-positive S. aureus is a major pathogen responsible for various community-onset and 
hospital acquired infections. It causes skin and soft tissues infections, surgical site infections, bone 
infections pneumonia, bacteremia, endocarditis and joints infections [1–3]. The nasal carriage of  
S. aureus in healthy adults was reported to be around 20%–30% of the population. Colonization clearly 
increases the risk for subsequent infection [4,5]. At present the β-lactam antibiotics are the preferred 
drugs against S. aureus infections. Antibiotic resistant staphylococci strains are a major public health 
concern since the bacteria can easily circulate in the environment. S. aureus has developed resistance 
to the β-lactam antibiotics due to synthesis of chromosomal or plasmid encoded β-lactamases [4–6].  
In comparison with methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant 
Staphylococcus aureus (MRSA) strains pose more problems, since invasive MRSA infections are 
associated with greater costs and limited treatment options [7]. 
Propolis (bee glue) is a natural resinous substance produced by honeybees (Apis mellifera) from 
plants’ buds and exudates, modified by addition of bees’ salivary secretions and wax [8,9].  
It has been the subject of scientific interest for its diverse range of biological properties, including  
anti-inflammatory [10,11], immunomodulatory [12,13], anti-carcinogenic [14,15], antioxidant [16,17], 
radioprotective [18], antiviral [19], and antifungal [20] effects. What is more, the antibacterial activity 
of propolis has been confirmed in many studies [19,21–25]. The wide spectrum of biological activities 
of propolis has been attributed to its complex chemical composition, which is however, dependent on 
the plant species from which it is harvested, and may be influenced by the geographical and climatic 
factors, as well as the type of foraging honeybee [8,24–27]. In addition, it has been demonstrated that 
there were some differences in the antibacterial activity of propolis extracts depending on the 
collection region [26] and the races of honeybee [21]. Nevertheless, due to the complex and 
multidirectional mechanism of action of all types of propolis on bacterial cell [28,29], development of 
resistance to this substance is complicated and unlikely. For this reason, in the light of a rapid and 
widespread emergence of bacterial strains resistant to classic chemotherapeutics [30], beneficial, 
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antimicrobial properties of propolis may be helpful in treatment of current bacterial infections. Studies 
on chemical composition of propolis from different geographical regions showed characteristic classes 
of compounds which correlated with selected plant sources. The most frequent techniques currently 
used for chemical composition analysis of propolis are spectrophotometric methods (UV-VIS,  
HP-TLC), high performance liquid chromatography (HPLC-DAD) coupled with different detectors, 
and gas chromatography-mass spectrometry (GC-MS) [31–33]. 
Many reports showed that S. aureus appears to be naturally susceptible to propolis [34]. Recent 
studies [8] revealed that propolis exerts synergistic effects with antibiotics, acting on the bacterial wall 
structure and ribosomes function, but it does not seem to interact with antibiotics acting on DNA or 
folic acid biosynthesis [35]. The mechanism of propolis antibacterial activity seems to be linked to 
some of its components. The potent bacteriostatic and bactericidal effects of propolis can be associated 
with their combined action manifested by inhibition of protein synthesis and bacterial growth by 
preventing cell division [36,37]. 
Particularly, the notion of using a combination of propolis and antibiotics to augment antibacterial 
therapy appears promising [34,38–43]. Some in vitro studies indicated evident synergism between 
propolis and antibiotics with a clear decrease of minimal inhibitory concentrations (MICs) for tested 
drugs [28,39], while in others this effect was less obvious [42], or not observed [41]. The results of the 
research carried out by Fernandes Junior et al., demonstrated the synergism between EEP and those 
antibacterial agents that interfere with bacterial protein synthesis, e.g. chloramphenicol, gentamicin, 
netilmicin, tetracycline and clindamycin [38]. The antibacterial activity of propolis, together with its 
potential to enhance the antimicrobials efficacy due to possible synergistic interactions, could be 
especially advantageous in the treatment of S. aureus infections, which currently represent a significant 
burden on healthcare systems across the world [44]. 
Thus, since there is a great and still growing need for the enhancement of therapy of infections 
caused by different S. aureus strains, the objective of this study was to assess the in vitro antimicrobial 
activity of ethanolic extract of Polish propolis (EEPP) against MSSA and MRSA clinical isolates. To 
make sure that bacterial strains were identified unambiguously the Polymerase Chain Reaction-Restriction 
Fragment Length Polymorphism (PCR-RFLP) technique with XapI and Bsp143I restriction enzymes 
was applied. The investigation of the activity of the EEPP alone and in combination with selected 
antistaphylococcal drugs on MSSA and MRSA cultures was also evaluated. 
2. Results and Discussion 
Quantitative analyses of ethanolic extracts of propolis are presented in Figure 1. Figure 1 represents a 
typical HPLC chromatogram of EEPP. Qualitative and quantitative analysis of selected flavonoids and 
phenolic acids was carried out, with the identification of pinocembrin, kaempferol, galangin, chrysin, 
apigenin, quercetin, gallic acid, ferullic acid, caffeic acid, caffeic acid phenethyl ester, p-coumaric acid and 
cinnamic acid. The flavonoid compounds identified in this study included flavones, flavanones, 
flavanolols, flavonols and chalcons. Most flavonoid compounds displayed the typical pattern of ―poplar‖ 
propolis. Several studies showed that flavonoids have antimicrobial, anticancer, antioxidant action. It is 
known that the amount of phenolic and flavonoid constituents varies widely according to propolis types 
and seasonal factors. The HPLC analysis showed that flavonoid compounds of Polish propolis are similar 
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to other ethanolic extracts of propolis, especially of European origin [17,24,26,28,36]. We made the 
conclusion that Polish propolis possesses significant amounts of biologically active compounds  
belonging to the classes of phenolic acids, and different classes of flavonoids (flavones/flavonols, 
flavanones/dihydroflavonols or other phenols) and can be subjected to other 'validated' methods for 
European poplar type propolis. Therefore, the multi-directional interactions among the various chemical 
compounds in propolis seem to be the essential biological activities when considering its antibacterial 
effects against pathogens. 
Figure 1. HPLC chromatogram of propolis ethanolic extract from Poland. 1-Cinnamic acid 
(Rt-5.20); 2-p-Coumaric acid (Rt-5.69); 3-Ferulic acid (Rt-6.23); 4-Gallic acid (Rt-6.98); 
5-Caffeic acid (Rt-7.36); 6-Caffeic acid phenethyl ester (Rt-8.63); 7-Pinobaksin (Rt-8.97); 
8-Kaempferol (Rt-9.34); 9-Apigenin (Rt-10.40); 10-Pinocembrin (Rt-10.92); 11-Quercetin 
(Rt-13.19); 12-Chrysin (Rt-13.93); 13-Galangin (Rt-14.72); 14-Acecetin (Rt-17.46);  
15-Kampferide (Rt-21.67); Rt- retention time (min). 
 
According to the standard and molecular method 10 clinical isolates were classified as belonging to 
the Staphylococcus aureus species (Table 1, Figure 2).  
Figure 2. Identification of mecA gene fragment (533 bp). W1—S. aureus MSSA ATCC 
25923; W2—S. aureus MRSA ATCC 43300; 1–10 S. aureus clinical isolates; M-100–1000 
bp marker, (+) positive control, (−) negative control. 
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Catalase positive, coagulase positive and mannitol fermenting staphylococcal strains were identified 
biochemically by the API STAPH system. The molecular species identification of coagulase-positive 
staphylococci by PCR-RFLP technique with XapI and Bsp143I restriction enzymes confirmed that all 
isolates were S. aureus strains. 
Table 1. The phenotypic (Cefoxitin test) and genetic (PCR mecA gene) assessment of  
S. aureus strains susceptibility to methicillin. 
Strain Cefoxitin test mecA MSSA/MRSA 
S. aureus 1 17 mm + MRSA 
S. aureus 2 34 mm − MSSA 
S. aureus 3 34 mm − MSSA 
S. aureus 4 33 mm − MSSA 
S. aureus 5 22 mm + MRSA 
S. aureus 6 34 mm − MSSA 
S. aureus 7 34 mm − MSSA 
S. aureus 8 13 mm + MRSA 
S. aureus 9 16 mm + MRSA 
S. aureus 10 14 mm + MRSA 
S. aureus W1 35 mm − MSSA 
S. aureus W2 21 mm + MRSA 
W1: S. aureus MSSA ATCC 25923; W2: S. aureus MRSA ATCC 43300. 
The broth microdilution method was used to determine the MICs of the EEPP against 12 S. aureus 
strains. EEPP displayed varying degree of activity against S. aureus with MIC values ranging from 
0.39 mg/mL to 0.78 mg/mL (Tables 2 and 3). The average MIC was 0.54 ± 0.22 mg/mL, MIC50 and 
MIC90 values were 0.39 mg/mL and 0.78 mg/mL, respectively. The MBC values of the EEPP ranged 
from 0.78 mg/mL to 3.13 mg/mL. 
Table 2. Susceptibility of S. aureus MSSA strains to EEPP (MIC and MBC values in mg/mL). 
Strain 2 3 4 6 7 W
1 
MIC EEPP (mg/mL) 0.39 0.39 0.78 0.78 0.78 0.39 
MBC EEPP (mg/mL) 1.56 1.56 3.13 3.13 1.56 3.13 
W1: S. aureus ATCC 25923. 
Table 3. Susceptibility of S. aureus MRSA strains to EEPP (MIC and MBC values in mg/mL). 
Strain 1 5 8 9 10 W
2 
MIC EEPP (mg/mL) 0.39 0.39 0.39 0.39 0.78 0.78 
MBC EEPP (mg/mL) 3.13 3.13 0.78 0.78 3.13 3.13 
W2: S. aureus MRSA ATCC 43300. 
Values of MIC and MBC EEPP against MSSA strains were successively 0.59 ± 0.21 mg/mL and 
2.5 ± 0.85 mg/mL. In the case of MRSA strains the MIC and MBC were as follows: 0.52 ± 0.2 mg/mL 
and 2.35 ± 1.21 mg/mL. 
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The in vitro combined effect of EEPP and 10 antibacterial drugs (FOX, DA, E, CIP, TE, P, TOB, 
LIN, C, SXT) was tested using disk diffusion method-based analysis, and the results are shown in 
Figure 3. This analysis revealed synergism between EEPP and FOX, DA, TE, TOB, LIN, P, E, and SXT 
for all tested MSSA and MRSA strains. In the case of CIP and C synergism with EEPP was not observed. 
Figure 3. Inhibitory effect of 10 antimicrobial agents alone, and in combination with EEPP 
on 12 Staphylococcus strains evaluated by disk diffusion method. (A) FOX and 
FOX+EEPP; (B) DA and DA+EEPP; (C) E and E+EEPP; (D) CIP and CIP+EEPP; (E) TE 
and TE+EEPP; (F) P and P+EEPP; (G) TOB and TOB+EEPP; (H) LIN and LIN+EEPP; 
(I) C and C+EEPP; (J) STX and STX+EEPP. MHA: Mueller-Hinton Agar; MHA with 
EEPP: MHA plus one-fourth of MIC90 of EEPP; blue bars: diameters of the growth inhibition 
zones (in mm) for antibiotic alone; red bars: diameters of the growth inhibition zones (in mm) 
for combined effect of antibiotics and EEPP; FOX: Cefoxitin; DA: Clindamycin;  
E: Erythromycin; CIP: Ciprofloxacin; TE: Tetracycline; P: Penicillin; TOB: Tobramycin;  
LIN: Linezolid; C: Chloramphenicol; STX: Trimethoprim+Sulfamethoxazole; K1: S. aureus 
ATCC 25923; K2: S. aureus MRSA ATCC 43300; * Wilcoxon Signed-Rank Test, statistical 
significant level at p < 0.05. 
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Figure 3. Cont. 
 
The analysis of bacterial growth after first 6 h of incubation showed that the growth of all strains in 
the medium supplemented with EEPP at concentrations ranging from 0.0125 to 0.39 mg/mL was not 
inhibited (Figure 4A). After 12 h of incubation, the growth of all strains was observed in the wells with 
the same range of EEPP concentrations (Figure 4B). After 24 h of incubation the growth of all MRSA 
and MSSA strains was observed at concentrations ranging from 0.0125 to 0.78 mg/mL (Figure 4C). 
Figure 4. Growth of S. aureus strains in the presence of different EEPP concentrations.  
(A) After 6 h of incubation; (B) After 12 h of incubation; (C) After 24 h of incubation;  
GC: Growth control. 
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Figure 4. Cont. 
 
 
The three-way ANOVA indicated that the growth of all S. aureus strains was significantly affected by 
EEPP concentration (p < 0.001) and incubation time (p < 0.001). The interaction between these factors was 
also significant (p < 0.001). The EEPP concentration effect (40.12%), incubation time (21.10%), and 
interaction between concentration and incubation time (20.23%) explained most of variance (Table 4). 
Table 4. Multivariate analysis of variance by three-way ANOVA of S. aureus strains 
susceptibility to EEPP 
Source of  
variation 
df Sum of  
squares 
Mean  
squares 
Variance  
explained (%)  
F p 
Strain (S) 11 0.67 0.06 0.71 27.2 <0.001 
Time (T) 2 19.8 9.9 21.10 4414.6 <0.001 
Concentration (C) 11 37.65 3.42 40.12 1526.5 <0.001 
S x T 22 1.46 0.07 1.56 29.5 <0.001 
S x C 121 6.74 0.06 7.18 24.8 <0.001 
T x C 22 18.99 0.86 20.23 384.9 <0.001 
SxTxC 242 8.54 0.04 9.01 15.7 <0.001 
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In this study; MIC EEPP values ranged from 0.39 to 0.78 mg/mL, while MBC values ranged from 
0.78 to 3.13 mg/mL. For MRSA strains, average MIC values were 0.52 ± 0.2 mg/mL, and for MSSA 
strains 0.59 ± 0.21 mg/mL. The MBC average values were similar for MRSA and MSSA strains, and 
found to be 2.35 ± 1.21 mg/mL and 2.35 ± 0.86 mg/mL, respectively. The MICAB average values were 
similar for MRSA and MSSA strains, and found to be 0.41 ± 0.22 mg/mL and 0.42 ± 0.31 mg/mL, 
respectively. The ethanol in EEPP was not responsible for the anti-staphylococcal activity of EEPP 
when compared to 70% ethanol control. 
It was previously reported that ethanolic extract of propolis showed various inhibitory activities 
against different microorganisms when tested in vitro [22,26,34,43,45,46] and in vivo [47]. In the study 
of Takaisi-Kikuni and Schilcher [29], some mechanisms of propolis activity on bacterial growth have 
been discussed. Havsteem [36] and Oksuz et al. [37] suggested that the specific propolis ingredients 
inhibit protein synthesis and bacterial growth by preventing cell division, resulting in the formation of 
pseudo-multicellular bacterial forms. Galangin and caffeic acid from EEP are enzymatic inhibition 
agents responsible for an inhibition of bacterial growth and proliferation. In addition, some active 
substances composing propolis may disorganize the cytoplasmic membrane and cell wall, with the 
effect of a partial bacteriolysis. Flavonoids affect bacterial membrane potential and cause permeability 
alteration within the inner microorganisms membrane [28]. 
Numerous studies have shown that the antimicrobial effect of EEP may vary according to the 
geographic region, as the propolis samples from different locations may exhibit different chemical 
composition. Seidel et al. [26] presented an evaluation of the antibacterial activity of 40 propolis 
samples collected from various locations worldwide. The propolis samples from Africa and Asia 
showed moderate activity, with MICs ranging from 0.0156 to >0.5 mg/mL and 0.0078 to >0.5 mg/mL, 
respectively. Samples from North and South America and samples collected in Europe displayed 
similar anti-staphylococcal activity, with the MIC values in the range of 0.125 to >0.5 mg/mL.  
Kilic et al. analyzing EEP effect on MRSA strains reported that MIC values of propolis samples from 
three different regions of Turkey, i.e. Mamak and two Kemaliye locations varied and amounted to 
0.018 ± 0.008, 0.162 ± 0.073, and 0.101 ± 0.040 mg/mL, respectively [48]. 
The results presented by Berretta et al. [49] demonstrated that the MBC of three samples of 
standardized propolis extract tested against S. aureus ATCC 25923 and S. aureus ATCC 43300 were 
in the range from 6.96 to 7.02 mg/mL and 3.48 to 3.51 mg/mL respectively. 
In the present study for the same reference strains the EEPP MBC values were lower (3.13 mg/mL) 
showing higher bactericidal activity of Polish propolis’ extract. The diverse antimicrobial activity of 
EEP shown by many authors and in our manuscript can be due to the differences in the origin of 
propolis, and its qualitative and quantitative composition. 
Wojtyczka et al. [25] showed the antistaphylococcal activity of the Polish EEPP against 11 S. 
epidermidis strains using the broth microdilution method. In this study EEPP displayed varying 
degrees of activity against CoNS with MIC in the range of 1.56–0.78 mg/mL. The average MIC was 
1.13 ± 0.39 mg/mL while calculated MIC50 and MIC90 were 0.78 mg/mL and 1.56 mg/mL, respectively. 
Investigated hospital-acquired clinical isolates revealed varying susceptibility to antibiotics. Apart 
from the common resistance to -lactam antibiotics, MRSA may often demonstrate an increased 
resistance towards other groups of antibiotics. Our study on the influence of EEPP on MSSA and 
MRSA strains showed no significant differences, both MIC and MBC values obtained for these strains 
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were relatively similar. This may lead to the conclusion that EEPP demonstrates an essential  
anti-staphylococcal activity not associated with beta-lactam antibiotics. Gonsales et al. observed the 
antibacterial activity of propolis using a diffusion method, in which EEP inhibited S. aureus growth, 
with diameters of the growth inhibition zones ranging from 8 to 13 mm [50]. Similar results were 
obtained by Stepanovic et al. In their study, the zone of microbial growth inhibition for 13 propolis 
samples obtained from different geographic regions of Serbia were in the range from 9 to 13 mm [43]. 
To estimate the combined effect of EEPP with a set of widely used antibiotics, the propolis in 
concentrations which did not by itself inhibit bacterial growth were used on solid MHA plates in the 
disk diffusion assay.  
MIC is usually measured by the broth dilution method and the convenient disk diffusion method, 
however the convenient disk diffusion method-based analysis is also used frequently to estimate drug 
susceptibility. These methods, using visual evaluation of bacterial growth in the presence of a tested 
compound, do not take into the consideration the cell metabolism. Therefore, a special technique is 
required for the assessment of bactericidal activity. 
In our study, the addition of EEPP at a concentration equal to ¼ of MIC90 (0.2 mg/mL) to MHA 
medium significantly increased sensitivity of S. aureus strains to DA (p = 0.018), TET (p = 0.005), 
TOB (p = 0.033), LIN (p = 0.005), and SXT (p = 0.018). Such synergy between EEPP and antibiotics 
was also observed for FOX (p = 0.067), E (p = 0.201) and P (p = 0.173), but the values did not reach 
statistical significance. In particular, a strong combined effect was observed in the case of TET and 
SXT, for which diameters of the growth inhibition zones on MHA medium with addition of EEPP 
were larger by 11–12 mm that the measured on MHA medium without EEPP. For the remaining 
antibiotics (FOX, DA, CIP, TOB, LIN) tested in combination with EEPP, the diameters of the growth 
inhibition zones were larger by 4–8 mm than that measured on MHA medium without EEPP. 
Synergistic effects of propolis and antibiotics on the growth of S. aureus have been reported 
previously by Krol et al. [34]. However, this effect was significant only at a propolis concentration of 
0.6 mg/mL, while in our experiment the effect appeared at 0.2 mg/mL EEPP concentration. 
EEP is known to contain a number of antimicrobial compounds, such as polyphenols and 
flavonoids. The antimicrobial and resistance modifying potentials of natural compounds have been 
reported by Cushnie and Lamb [51]. This suggests that the synergy with antibiotics observed in this 
study could be attributed to such compounds. Some of these compounds, like polyphenols, have been 
shown to exert their antibacterial action through membrane perturbations. This perturbation of the cell 
membrane coupled with the action of β-lactams on the transpeptidation of the cell membrane could 
lead to the enhanced antimicrobial effect [52]. 
3. Experimental 
3.1. Ethanolic Extract of Polish Propolis (EEPP) 
Propolis samples produced by honeybees (Apis mellifera) from an apiary in Kamianna near Nowy 
Sącz in southern Poland constituted the material for the study. This area is primarily rich in black 
poplar (Populus nigra), birch (Betula alba), alder (Alnus glutinosa), beech (Fagus sylvatica) and 
horsechestnut (Aesculus hippocastanum). Hand collected propolis were kept desiccated in the dark 
Molecules 2013, 18 9633 
 
 
prior to its processing. Propolis was subjected to 14 days of extraction in order to obtain the ethanol 
extract of propolis, which was later dissolved in 70% ethanol to obtain a 100 mg/mL working 
concentration. Briefly, the samples were ground mechanically and bottled in 10 g portions. The 10 g 
portions were put into flask and 100 g of 70% ethanol (w/v) was added. The flask was placed on a 
rotary shaker in a dark, closed room for two weeks in room temperature. After this period, the extract 
was cooled in 4 °C for 24 h in order to precipitate all insoluble particles, which were removed from the 
propolis extract by filtration through filter paper (Whatman no. 4). Next, the obtained filtrate was 
evaporated to dryness at 40 °C using a rotary vacuum evaporator. In order to prepare a working 
concentration, the brown colored viscous substance was dissolved in 70% ethanol.  
3.2. HPLC-DAD Analysis of EEPP 
To determine the chemical composition of EEPP a high performance liquid chromatography 
method was applied. Analysis was run on a Varian 920-LC HPLC (Harbor City, CA, USA), equipped 
with a 900-LC model autosampler, gradient pump, 330 model DAD, and the Galaxie software for data 
acquisition and processing. Separation was achieved using gradient mode on a Pursuit C18 (5 μm 
particle size) column (250 × 4.6 mm id; Varian; Cat. no. 1215–9307) using water, formic acid (95:5, 
v/v) (solvent A) and acetonitrile (solvent B). The elution was carried out at a flow rate of  
0.6 mL/min. The separations were performed with a gradient elution: 20%–30% solvent B (for 15 
min), 30% solvent B (15–28 min), 30%–80% solvent B (28–50 min), 80% solvent B (50–54 min), 
80%–40% solvent B (54–60 min) and 40%–20% solvent B (60–65 min) The detection was monitored 
at 254 and 340 nm and the components identified by comparison with standards acquired 
commercially or isolated during previous work. EEPP were filtered with a 0.22 μm filter (Millipore) 
prior to injection of 20 μL into the HPLC system. Standard mixtures in ethanol containing chrysin, 
apigenin, acacetin, galangin, kaempferol, kaempferid, quercetin, pinostrombin, gallic acid, ferulic acid, 
cinnanic acid, o-coumaric acid, m-coumaric acid, p-coumaric acid, caffeic acid and caffeic acid 
phenylethyl ester (CAPE) were prepared from standard stock solutions (each at a concentration  
of 0.1 mg/mL in ethanol). All phenolic compounds were purchased from Carl Roth GmbH (Karlsruhe, 
Germany) and Sigma Chemical Company (St. Louis, MO, USA). 
3.3. Bacterial Strains 
The antibacterial activity of EEPP was assessed against ten coagulase-positive S. aureus strains 
isolated from blood clinical samples, and two reference strains of S. aureus ATCC 25923 and  
S. aureus ATCC 43300 as the MSSA and MRSA positive controls, respectively. Isolates were 
identified by conventional methods, including Gram staining, colony morphology, hemolysis, test for 
catalase, coagulase activity and anaerobic fermentation of mannitol. Catalase positive and coagulase 
positive staphylococcal isolates were identified by the API STAPH system (bioMerieux, Marcy 
l’Etoile, France) according to the manufacturer’s instructions. All bacterial strains were stored in Trypticase 
Soy Broth (TSB) medium with 20% of glycerol at −86 °C, until further analyses were performed. 
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3.4. Molecular Identification of Isolated Strains—PCR-RFLP Analysis of dnaJ Gene 
For molecular analyses, bacterial genomic DNA was extracted with the GeneMATRIX Tissue & 
Bacterial DNA Purification KIT (EuRx Ltd., Gdańsk, Poland) according to the manufacturer’s 
recommendations and used for the PCR-RFLP analysis as described previously by Shah et al. [53]. 
Briefly, the dnaJ primers SA-(F) (5′-GCC AAA AGA GAC TAT TAT GA-3′) and SA-(R)  
(5′-ATT GYT TAC CYG TTT GTG TAC C-3′) were used to amplify the dnaJ gene fragment. The 
PCR amplification was performed using 10 × PCR RED master mix kit (BLIRT SA, Poland) in a MJ 
Mini Personal Thermal Cycler (Bio-Rad, Hercules, CA, USA). The PCR products were visualized 
under UV light after the electrophoretic separation in a 1.5% agarose gel (Promega, Madison, WI, 
USA) with ethidium bromide (EtBr). To identify isolated staphylococci strains, the PCR products were 
treated with 10 U of the XapI or Bsp143I restriction enzymes to obtain the species-specific restriction 
profiles. Digestions were performed in a total volume of 15 µL, with 5 µL of the PCR products, 1 µL 
of reaction buffer and 10 U of the XapI or Bsp143I endonucleases (Fermentas, Vilnius, Lithuania) for 3 h 
at 37 °C [54]. The obtained fragments were separated in a 2% agarose gel with EtBr (Promega), visualized 
under the UV light, and checked for size against 1 Kb HypeLadderIV (BLIRT SA, Gdańsk, Poland) 
molecular weight marker. 
3.5. MSSA and MRSA Detection 
3.5.1. Cefoxitin Test 
MRSA isolates were detected using cefoxitin disk diffusion method. A colony suspension 
equivalent to 0.5 McFarland was inoculated to Mueller-Hinton agar (MHA—BTL, Łódź, Poland), with 
a 30 μg cefoxitin disk (EMAPOL, Gdańsk, Poland) and interpreted after 20 h of incubation at 35 °C. 
MRSA strains were identified using a breakpoint of ≤21 mm zone diameter size for cefoxitin disks. 
3.5.2. The mecA Gene Detection 
PCR detection of the mecA gene was performed with the primers and reaction conditions described 
previously by Murakami et al. [55]. MecA primers complementary to the penicillin binding protein 
(PBP2’) coding region (F) (5’-AAA ATC GAT GGT AAA GGT TGG C-3’) and (R) (5’-AGT TCT 
GCA GTA CCG GAT TTG C-3’) were used. The PCR amplification was performed using 10 × PCR 
RED master mix kit (BLIRT SA) in a MJ Mini Personal Thermal Cycler (Bio-Rad). The PCR products 
of 533 bp were detected under UV light after electrophoretic separation in a 1.5% agarose  
gel (Promega) with EtBr. 
3.6. Antibacterial Susceptibility Testing 
3.6.1. Disk Diffusion Method 
All isolates were tested for antimicrobial susceptibility by the disk diffusion method-based analysis, 
using MHA and commercially available disks containing an antimicrobial agent according to the 
EUCAST recommendations [56]. For disk diffusion testing, 90 mm plates with the agar medium were 
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inoculated by swabbing the agar with a swab soaked in a bacterial suspension of 1 × 10
8
 cells/mL. Disks 
(EMAPOL) containing penicillin (P) 1 IU, erythromycin (E) 15 µg, clindamycin (DA) 2 µg, cefoxitin 
(FOX) 30 µg, ciprofloxacin (CIP) 5 µg, tobramycin (TOB) 10 µg, chloramphenicol (C) 30 µg, linezolid 
(LIN) 10 µg, tetracycline (TE) 30 µg or trimethoprim+sulfamethoxazole (SXT) 1.25 + 23.75 µg were used 
for the analysis of antimicrobial susceptibility. 
The combined effect of antibiotics and EEPP was studied using plates with MHA plus one-fourth of 
MIC90 of EEPP, which was considered as a sub-inhibitory concentration [38,57]. Disks were placed onto 
agar surface and gently pressed to ensure contact using sterile forceps. Plates were incubated at 35 °C for 
20 h in air. The susceptibility testing of each antibiotic for each isolate and the reference strains was 
performed in triplicates. After the incubation period diameters of the growth inhibition zones (in mm) 
were measured for each strain, and the mean values were calculated. 
3.6.2. Microdilution Method 
MICs of EEPP were determined by the broth microdilution liquid and growth inhibition method. 
Growth inhibition assays were performed in the sterile Nunc 96-well plates, in a final volume of  
200 μL [58,59]. The cell concentrations were estimated from the optical densities at 600 nm 
wavelength with the formula CFU/mL = A600 (3.8 × 10
8
), where CFU was the number of colony-forming 
units. One hundred microliters of mid-logarithmic-phase bacterial cultures (5 × 10
5
 CFU/mL) in 
Mueller-Hinton broth (MHB) was added to 100 μL of serially diluted EEPP (12.5 to 0.01 mg/mL). 
Wells containing MHB with bacterial inoculum only served as the bacterial growth control (GC). 
Additional controls included MHB alone (medium sterility control), MHB with different 
concentrations of EEPP, and MHB with different concentration of 70% ethanol and bacterial 
inoculum. All samples were prepared in triplicates. Microplates were incubated at 37 °C for 20 h, and 
the bacterial cell growth was assessed by measuring the optical density of cultures at 600 nm 
wavelength with a Multiskan EX microplate reader (Thermo Electron Corp., Vantaa, Finland) [60,61]. 
The MICs were defined as the lowest concentration that completely inhibits bacterial growth [58,59,61]. 
The MIC50 represents the MIC value at which ≥50% of the isolates in a test population are inhibited 
and is equivalent to the median MIC value. The MIC90 represents the MIC value at which ≥90% of the 
strains within a test population are inhibited; the 90
th
 percentile [62]. 
The MBCs were expressed as the lowest concentration of an antimicrobial agent (mg/L), that  
in vitro reduces the number of bacteria by 99.9%, within a defined period of time [56]. To determine 
the MBC value of EEPP 100 µL aliquots from each EEPP dilution, were transferred into MHA plates 
and incubated at 37 °C for 20 h. After incubation period, the number of colonies was calculated, and 
the initial CFU/well retrospectively determined [63]. 
3.7. Statistical Analyses 
To determine the percentage of the variation attributable to the factors such as bacterial strains, 
time, and concentrations the results concerning the bacterial growth were analyzed by a three-way 
analysis of variance (ANOVA). The results from synergism assay were submitted to the Wilcoxon 
Signed-Rank Test comparing the values (mm) of the inhibitory zone in the disk diffusion method. All 
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statistical analyses were performed using the Statistica 10.0 PL software package, assuming the 
statistical significance level of p < 0.05. 
4. Conclusions  
Our data showed that clinical strains of MSSA and MRSA with different drug resistance patterns 
were susceptible to EEPP. The action of EEPP was manifested by both growth inhibition of 
microorganisms (MIC) and bactericidal (MBC) activity. What is more, the observed synergistic effects 
of EEPP with commonly used antibiotics should induce further research on including EEPP in 
antimicrobial therapy schemes to augment their potential toward clinical strains of S. aureus. 
Despite the fact, that the results presented in our study are promising, further randomized studies 
are needed to determine the clinical effectiveness of the synergistic action of propolis and 
antimicrobial drugs on staphylococci infections resistant to standard treatments. The propolis extract 
may facilitate and augment the antibiotic action by correcting the pharmacokinetic and pharmaco-dynamic 
properties and thus potentiate its biological action.  
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